Form 4: Erasca Inc. Officer Acquires Stock Options
SEC Form 4 Filing
Chief Medical Officer of Erasca, Inc., Shannon Morris, reports acquisition of stock options.
Summary
- On June 20, 2024, Shannon Morris, Chief Medical Officer of Erasca, Inc., acquired 137,142 stock options at an exercise price of $2.03.
- These options vest monthly over a four-year period, starting on June 20, 2024, contingent upon continuous service to Erasca.
- The options expire on June 19, 2034.
- Following the transaction, Morris directly owns 137,142 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants. It's generally positive to see management incentivized, but it doesn't provide specific insights into the company's performance.
Positives
- The acquisition of stock options by a key officer aligns their interests with those of the shareholders, potentially incentivizing performance and company growth.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies to align management's interests with shareholders'.
Stakeholder Impact
- Shareholders may view this as a positive sign, aligning management's interests with the company's success.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of the stock option transaction and start of vesting period. |
| 06/19/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.